TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01221077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSI-906
Description: As of 01 March 2013, OSI-906 is no longer being administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Erlotinib
Description: Erlotinib administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: As of 01 March 2013, the matching placebo is no longer being administered
Study: NCT00004228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given IV
Study: NCT02676466

Intervention type: OTHER
Group type: OTHER
Intervention: Cellulose Based (Losartan Placebo)
Description: The placebo cellulose based capsules will be identical in shape, color, taste and weight as the losartan capsules.

Intervention type: OTHER
Group type: OTHER
Intervention: Cellulose Based (Losartan Placebo)
Description: The placebo cellulose based capsules will be identical in shape, color, taste and weight as the losartan capsules.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cellulose Based (Losartan Placebo)
Description: The placebo cellulose based capsules will be identical in shape, color, taste and weight as the losartan capsules.
Study: NCT04624438

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric training with electromyostimulation
Description: Each training session (18 in total) consisted of forty 4-s contractions separated by 20 s inter-contraction intervals. The exercise intensity was close-to-identical among the sessions (60 %MVC). The force intensity was determined individually during pretest where EMS was delivered at maximal tolerable dose. Electrical stimulation was 6.25-second long and was followed by a rest period of 20-second (duty cycle 15%). Stimulation characteristics were selected among the Compex commercially available strength programs. The stimulation intensity was monitored on-line and determined by the subject at the start of each EMS session according to his/her pain threshold to produce a force corresponding to at least 60% of the pretest MVC score.
Study: NCT04624438

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric training with voluntary activation
Description: Each training session (18 in total) consisted of forty 4-s contractions separated by 20 s inter-contraction intervals. The exercise intensity was close-to-identical among the sessions (60 %MVC). Participants were required to reach the proscribed force level only through voluntary activation of QF. To attain the same contraction/rest ratio as in EMS, automated audible signals were delivered in accordance with the contraction-rest pattern produced by the muscle stimulation device. To ensure participants produced 60% of individual MVC during each contraction the force level was measured with a force transducer and real-time feedback was provided on a computer screen.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric training with combination of electromyostimulation and voluntary activation
Description: Each training session (18 in total) consisted of forty 4-s contractions separated by 20 s inter-contraction intervals. The exercise intensity was close-to-identical among the sessions (60 %MVC). The proscribed force level was reached by the simultaneous action of EMS and VOLUNTARY. Each contraction was 6.25-second long and was followed by a rest period of 20-second (duty cycle 15%). Electrical stimulation corresponded to 30% of MVC, while the remaining 30% was achieved through voluntary muscle activation. To ensure participants produced a force corresponding to 60% of MVC during each contraction the force level was measured with a force transducer and real-time feedback was provided on a computer screen.
Study: NCT00004228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given IV
Study: NCT03451292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albutein 20% Injectable Solution
Description: Within 96 hours after discharge and following randomization, subjects will receive the first Albutein 20% infusion at the dose of 1.5 g/kg body weight (maximum 100 grams per subject). Thereafter, subjects will receive Albutein 20% infusions at the dose of 1.5 g/kg body weight (maximum 100 grams per subject) every 10 ± 2 days for the rest of the study (up to a maximum of 12 months). Subjects in this treatment group will also receive SMT.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical treatment
Description: Subjects will receive SMT according to published guidelines for the management of decompensated cirrhosis.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard medical treatment
Description: Subjects will receive SMT according to published guidelines for the management of decompensated cirrhosis.
Study: NCT03283553

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Checklist, MyChart, OpenNotes
Description: 1) Patient-family agenda-setting checklist, 2) Facilitated proxy registration for MyChart, and 3) Education on access to doctor's electronic visit notes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Routine medical oncology care
Study: NCT04304469

Intervention type: OTHER
Intervention: surveys
Description: delivery of the survey at a domestic violence consultation

Intervention type: OTHER
Intervention: follow-up
Description: follow-up of women 6 months after their consultation
Study: NCT00508976

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Injected bupivacaine post-operatively
Description: Patients will receive 30 ml of 0.9% normal saline divided equally and injected prior to port site incision, then 10ml of 0.9% normal saline streamed via port directed at operative field, then 10ml of 0.9% normal saline aerosolized into the coelomic cavity prior to deflation, and our current standard of care, which is 30ml of 0.5% bupivacaine, divided equally between the five port-sites, injected at the end of the operation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Streamed bupivacaine versus streamed normal saline
Description: Patients will receive 30ml of 0.9% normal saline divided equally and injected prior to port site incisions, then 10ml of 0.5% bupivacaine streamed via port directed at operative field, then 10ml of 0.9% normal saline aerosolized into the coelomic cavity prior to deflation and our current standard of care, which is 30ml of 0.5% bupivacaine, divided equally between the five port-sites, injected at the end of the operation.
Study: NCT00508976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aerosolized bupivacaine versus aerosolized saline
Description: Patients will receive 30 ml of 0.9% normal saline divided equally and injected prior to port site incision, then 10ml of 0.9% normal saline streamed via port directed at operative field, then 10ml of 0.5% bupivacaine aerosolized into coelomic cavity prior to deflation and our current standard of care, which is 30ml of 0.5% bupivacaine, divided equally between the five port-sites, injected at the end of the operation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injected lidocaine pre-incision vs saline pre-incision
Description: Patients will receive 30ml of 1% lidocaine divided equally and injected prior to port site incisions, then 10ml of 0.9% normal saline streamed via port directed at operative field, then 10ml of 0.9% normal saline aerosolized into the coelomic cavity prior to deflation and our current standard of care, which is 30ml of 0.5% bupivacaine, divided equally between the five port-sites, injected at the end of the operation.
Study: NCT04555330

Intervention type: DEVICE
Group type: OTHER
Intervention: Physical activity measurement
Description: To assess physical activity two small tri-axial accelerometers embedded in medical Band-Aids will be used. The accelerometers are discretely worn on the lateral aspect of the thigh.~The accelerometers sample accelerations continuously during hospitalisation and are connected wirelessly to a tablet that via an inbuilt algorithm classify the recordings as bedridden (lying down), sitting, standing, and walking.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Physical activity measurement
Description: To assess physical activity two small tri-axial accelerometers embedded in medical Band-Aids will be used. The accelerometers are discretely worn on the lateral aspect of the thigh.~The accelerometers sample accelerations continuously during hospitalisation and are connected wirelessly to a tablet that via an inbuilt algorithm classify the recordings as bedridden (lying down), sitting, standing, and walking.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visual Feedback
Description: The tablet will be placed on the patients bedside table and provides feedback on the amount of physical activity and motivational imagesand texts that will be visible for the patients, the health care staff and visitors.
Study: NCT03172624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: nivolumab 3 mg/kg every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: nivolumab 3 mg/kg every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: ipilimumab 1 mg/kg every 6 weeks (1 cycle= 6 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: ipilimumab 1 mg/kg every 6 weeks (1 cycle= 6 weeks)
Study: NCT01903811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Given IV
Study: NCT00004228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV
Study: NCT01903811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01231347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 479
Description: AMG 479 12 mg/kg administered intravenously on days 1 and 15 of a 28 day cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered intravenously on days 1 and 15 of a 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 479
Description: AMG 479 20mg/kg administered intravenously on days 1 and 15 of a 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: gemcitabine 1000mg/m2 administered intravenously on days 1, 8 and 15 of a 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: gemcitabine 1000mg/m2 administered intravenously on days 1, 8 and 15 of a 28 day cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: gemcitabine
Description: gemcitabine 1000mg/m2 administered intravenously on days 1, 8 and 15 of a 28 day cycle
Study: NCT03794778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin
Description: PLD 30 mg/m2, i.v.,d1; once every 21days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: paclitaxel 175 mg/m2, i.v.,d1; once every 21days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: carboplatin AUC 5, i.v.,d1; once every 21days,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: carboplatin AUC 5, i.v.,d1; once every 21days,
Study: NCT03326479

Intervention type: DIAGNOSTIC_TEST
Intervention: Caris Molecular Intelligence Profile
Description: A comprehensive biomarker testing
Study: NCT03682354

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intercostal Nerve Block with PCIA
Description: Intercostal nerve block consists in the injection of Ropivacaine (4 ml,0.5%) in related intercostal spaces. Patient-controlled intravenous analgesia regimen is conducted with sufentanil.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block (ESPB)
Description: Erector Spinae Plane Block consists in the injection of Ropivacaine (20ml, 0.5%), in the anatomical plane between the Erector Spinae muscles and transverse process, laterally to the spinous process of T5 . The catheter was inserted and secured in place under ecographic guidance, and a patient-controlled regional anesthesia regimen was conducted with 0.2% ropivacaine.
Study: NCT00743145

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inactive Marijuana (0% THC)
Description: Marijuana cigarette containing 0% THC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inactive Marijuana (0% THC)
Description: Marijuana cigarette containing 0% THC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Marijuana (5.5% THC)
Description: Marijuana cigarette containing 5.5% THC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Active Marijuana (5.5% THC)
Description: Marijuana cigarette containing 5.5% THC
Study: NCT03779360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate 0.05% topical formulation (crossover comparison):
Description: 2 day pre-treatment with clobetasol propionate 0.05% topical formulation applied twice daily on marked area on left or right side of the volar lower arm.~Clobetasol propionate 0.05% topical formulation (crossover comparison):~Clobetasol propionate is a potent synthetic corticosteroid with anti-inflammatory, anti-pruritic, and vasoconstrictive properties. Clobetasol propionate exerts its effect by binding to cytoplasmic glucocorticoid receptors and subsequently activates glucocorticoid receptor mediated gene expression. This results in synthesis of certain anti-inflammatory proteins, while inhibiting the synthesis of certain inflammatory mediators. Specifically, clobetasol propionate appears to induce phospholipase A2 inhibitory proteins, thereby controlling the release of the inflammatory precursor arachidonic acid from membrane phospholipids by phospholipase A2.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lipopolysaccharide
Description: As TLR4 agonist, purified lipopolysaccharide prepared from Escherichia Coli: 113: H10:K negative (U.S. Standard Reference Endotoxin) will be used. This LPS batch is manufactured in the US by the National Institute of Health (NIH). Subjects will receive two intradermal doses of LPS in each forearm on day 0 (4 LPS injections in total, except for subjects 1-6 who receive none and subjects 25-27 will receive 2 LPS injections, only in the right arm). The dose per injection is 10 ng.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lipopolysaccharide
Description: As TLR4 agonist, purified lipopolysaccharide prepared from Escherichia Coli: 113: H10:K negative (U.S. Standard Reference Endotoxin) will be used. This LPS batch is manufactured in the US by the National Institute of Health (NIH). Subjects will receive two intradermal doses of LPS in each forearm on day 0 (4 LPS injections in total, except for subjects 1-6 who receive none and subjects 25-27 will receive 2 LPS injections, only in the right arm). The dose per injection is 10 ng.
Study: NCT00743145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Marijuana (6.2% THC)
Description: Marijuana cigarette containing 6.2% THC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Active Marijuana (6.2% THC)
Description: Marijuana cigarette containing 6.2% THC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Naltrexone (12mg/70kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Naltrexone (12mg/70kg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Naltrexone
Description: Naltrexone (12mg/70kg)
Study: NCT03552458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactobacillus Reuteri Oral Solution [BioGaia]
Description: BioGaia Lactobacillus Reuteri drops

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo will be identical in physical appearance and color to the study agent and will be made by the manufacturer
Study: NCT03274271

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action planning
Description: Action planning is the behaviour change technique used to make users specify their goal (what they are going to do, when, where, ...).
Study: NCT00743145

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo naltrexone
Description: Naltrexone (0mg)
Study: NCT03274271

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action planning
Description: Action planning is the behaviour change technique used to make users specify their goal (what they are going to do, when, where, ...).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action planning
Description: Action planning is the behaviour change technique used to make users specify their goal (what they are going to do, when, where, ...).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action planning
Description: Action planning is the behaviour change technique used to make users specify their goal (what they are going to do, when, where, ...).
Study: NCT03569176

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Autism Glass
Description: The intervention uses the outward-facing camera on the google glasses to read facial expressions and provides social cues within the child's natural environment during usual social interaction and during games accessed via the smartphone application. Participants who receive the Google Glass intervention will be asked to use it for around 20 minutes 3 times a week with their parents or during ABA therapy.

Intervention type: DEVICE
Group type: OTHER
Intervention: Autism Glass
Description: The intervention uses the outward-facing camera on the google glasses to read facial expressions and provides social cues within the child's natural environment during usual social interaction and during games accessed via the smartphone application. Participants who receive the Google Glass intervention will be asked to use it for around 20 minutes 3 times a week with their parents or during ABA therapy.
Study: NCT00004228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV
Study: NCT03274271

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback and tips
Description: In this intervention, users receive tailored feedback on their current health behaviour and tips and tricks to reach their goals. This tips and tricks include the behaviour change technique 'eliciting social support'.
Study: NCT04294264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine and Tipiracil Hydrochloride
Description: Given PO
Study: NCT03215030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modakafusp alfa
Description: Modakafusp alfa intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modakafusp alfa
Description: Modakafusp alfa intravenous infusion.
Study: NCT00743145

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo naltrexone
Description: Naltrexone (0mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo naltrexone
Description: Naltrexone (0mg)
Study: NCT03602729

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breastfeeding education
Description: Breastfeeding education in three different forms: written/verbal/video

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breastfeeding education
Description: Breastfeeding education in three different forms: written/verbal/video

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breastfeeding education
Description: Breastfeeding education in three different forms: written/verbal/video
Study: NCT00723931

Intervention type: BIOLOGICAL
Intervention: Peginterferon alfa-2b (SCH 54031)
Description: Surveillance will be conducted after administration of peginterferon alfa-2b (administered according to the directions on the products' labeling). PegIntron Injection for surveillance is a weight-based dosing product administered at a dose of 0.5/1.0 ug/kg or 1.5 ug/kg. Administration of treatment is not part of this study.
Study: NCT05400915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Variltinib, Paclitaxel
Description: Varlitinib will be administered orally to the study participants at doses 300mg, BID in combination with the weekly intravenous infusion of Paclitaxel for 3 weeks with a rest period of 1 week.